Jeremy Blitzer

Dr. Blitzer is a co-founder and Managing Director of Potrero Hill Therapeutics. Jeremy was also Partner & VP Product Development at Synergenics, where he had both strategic and operational roles in Synergenics’s biopharmaceutical division, including evaluation of new drug discovery and development opportunities, formation of new companies, and day-to-day responsibility for nearly all aspects of advancing new drug candidates from inception through IND and clinical proof-of-concept. In particular, he had a key role in the discovery and development activities of Pathologica and BioEnergenix, which are both currently acquisition candidates with an open IND in the case of Pathologica. Synergenics, which owns and operates a portfolio of biotechnology, small-molecule therapeutics, diagnostic, and healthcare IT companies in the US and Europe, was founded in 2004 by William J. Rutter, a founder of Chiron Corporation and former head of UCSF's biochemistry and biophysics department. Prior to joining Synergenics, Jeremy obtained M.D. and Ph.D. degrees from Stanford University School of Medicine, as well as a bachelor’s degree in Chemistry from Duke University.